Halozyme Therapeutics, Inc.

Companies ink development and supply agreement for Enhanze SC

Published in Law and Health Weekly, April 30th, 2005

Halozyme Therapeutics, Inc., (HTI), a development-stage biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, and Baxter Healthcare Corp. announced that they have expanded their relationship by signing a development and supply agreement for Enhanze SC, Halozyme's recombinant human hyaluronidase enzyme (rHuPH20).

In August 2004, Halozyme Therapeutics and Baxter Healthcare Corp. signed an exclusive sales and marketing agreement, under which Baxter and Halozyme are equal partners in the commercialization of Enhanze SC, upon U.S. Food and Drug Administration (FDA) approval. Upon approval of the therapeutic by the FDA,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-04-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry